摘要:
Provided are compounds having an inhibitory effect on Mixed Lineage Kinases. Also provided are pharmaceutical compositions, methods of preparing the compounds, synthetic intermediates, and methods of using the compounds, independently or in combination with other therapeutic agents, for treating diseases and conditions which are affected by Mixed Lineage Kinase inhibition. Also provided are methods of treatment of neuropsychiatric disorders which comprise the inhibition of Mixed Lineage Kinases.
摘要:
Alternative chemical and/or solid state forms of Compound (I), processes to reprodυcibly make them and methods of treating patients using them. Formula (I) wherein 11.isobutyl-2-τnethyl-8-(2-pyrimidinylamino)-2,5,6, 11,12,13-hexahydro-4H- indazolo[5,4-α]pyrrolo [3,4-c]carbazol-4-one.
摘要:
The invention belongs in the field of organic chemistry and relates to a new shortened Pictet- Spengler type reaction for preparing isomerically pure ß-carboline compounds useful for the synthesis of tadalafil.
摘要:
Compounds of the following formula are provided for use with kinases: (I) wherein the variables are as defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds; methods and intermediates useful for making the compounds; and methods of using said compounds.
摘要:
Die Erfindung betrifft Verbindungen gemäß der allgemeinen Formel (I), die insbesondere als Strukturmimetika prolinreicher Peptide eingesetzt werden können und demgemäß in der Lage sind, PRM-Bindungsdomänen (proline-rich-motif binding domains) von Proteinen zu binden. Die Erfindung betrifft weiterhin die Verwendung dieser Verbindungen als pharmazeutische Wirkstoffe sowie die Verwendung der pharmazeutischen Wirkstoffe zur Behandlung von bakteriellen Erkrankungen, neurodegenerativen Erkrankungen sowie Tumoren.
摘要:
The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
摘要:
The present invention relates to purinone derivatives which are agonists of the HM74a receptor. Further provided are compositions and methods of using the compounds herein, and their pharmaceutically acceptable salts for the treatment of disease.
摘要:
Compounds of Formula I are inhibitors of FHV integrase and inhibitors of FHV replication (I), wherein m, n, X, R l , R 2 , R 3 , R 4 , R 5 , R 6 R 7 ; R 8 R 9 and R 10 are defined herein. The compounds are useful for the prophylaxis or treatment of infection by HTV and the prophylaxis, treatment , or delay in the onset of AIDS. The compounds are employed against HTV infection and ADDS as compounds per se or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.